Amyotrophic lateral sclerosis

A new way to effectively deliver a gene-silencing vector to adult amyotrophic lateral sclerosis (ALS) mice is reported by an international team headed by researchers at University of California San Diego School of Medicine[1]. The treatment results in long-term suppression of the degenerative motor neuron disorder if the treatment vector is delivered prior to disease… Read more

A computer generated-simulation has allowed scientists to see how a toxin produced by algal blooms in saltwater might cause Amyotrophic Lateral Sclerosis (ALS). Penn State College of Medicine researchers investigated an environmental toxin called β-Methylamino-L-alanine (BMAA) that has been linked[1] to significantly increased occurrence of sporadic amyotrophic lateral sclerosis in populations with frequent dietary consumption… Read more

Intestinal microbes, collectively termed the gut microbiome, may affect the course of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, researchers at the Weizmann Institute of Science have shown in mice. Progression of an ALS-like disease was slowed after the mice received certain strains of gut microbes or substances known to be secreted… Read more

A new study helps explain the cascade of problems that lead to neurodegeneration after stroke or traumatic brain injury, as well as in diseases like Alzheimer’s and Parkinson’s. It also suggests a potential strategy for therapy. “What this paper shows is if you lose these vascular cells, you start losing neurons. The link with neurodegeneration… Read more

A potential new biomarker and drug target for amyotrophic lateral sclerosis has been identified by research led by stem cell scientists at Harvard University. The study used stem cell models of human motor neurons to reveal the gene STMN2 as a potential therapeutic target, demonstrating the value of this human stem cell model approach in… Read more